Latest news and press releases about Phathom Pharmaceuticals, Inc. (PHAT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada.
Price
| Price | $7.69 |
| Market Cap | $622M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -1.86 |
| EV / EBITDA | -21.44 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 25.70% |
| Return on Invested Capital | -23.36% |
| Return on Assets | -30.29% |
| Gross Margin | 82.92% |
| Operating Margin | -16.96% |
| Net Margin | -41.34% |
Related companies: ANAB · BBOT · BCAX · KOD · NRIX · OCS · SANA
Explore sector: Healthcare · Biotechnology
More sections of PHAT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks